Anemia management in heart failure: a thick review of thin data

Pharmacotherapy
Brian F McBride, C Michael White

Abstract

Heart failure is defined as the inability of the heart to pump blood at an amount sufficient to meet the metabolic needs of the body. In heart failure, the inability to meet the body's metabolic needs is based on hemodynamic derangement and suboptimal oxygen-carrying capacity of the blood itself. Current pharmacologic therapy attempts to improve survival and reduce symptomatology by optimizing hemodynamics to increase oxygen delivery, but does not address oxygen-carrying capacity. Unfortunately, there is a high prevalence of anemia in patients with heart failure, which compromises oxygen-carrying capacity, is an independent predictor of mortality, and may be caused in part by pharmacologic agents that confer morbidity and mortality benefits in this population. Recombinant human erythropoietin supplementation improves the functional capacity of the failing myocardium, reverses and antagonizes the detrimental remodeling induced by autoimmune activity, and may reduce mortality and morbidity among patients receiving maximal pharmacologic therapy for heart failure. However, limited clinical data prohibit widespread recommendations for its use in patients with heart failure.

References

Dec 1, 1986·Journal of the American College of Cardiology·P AnversaG Olivetti
Apr 16, 1994·BMJ : British Medical Journal·J MayetS A McG Thom
Jun 1, 1996·Journal of the American Geriatrics Society·M W RichJ C Sperry
Jun 1, 1996·Journal of Cellular Physiology·M R WaldL Sterin-Borda
Mar 27, 1997·Biochemical and Biophysical Research Communications·K YoshiokaJ W Fisher
Jan 23, 1998·JAMA : the Journal of the American Medical Association·R B WeiskopfM A Moore
Jun 12, 1998·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·S AlbitarB Bourgeon
Oct 13, 1998·Journal of the American College of Cardiology·H DrexlerG Hasenfuss
Feb 19, 1999·Circulation Research·Y M KimT R Billiar
Feb 27, 1999·Journal of Cellular Physiology·P A Gregoli, M C Bondurant
Mar 15, 2000·Journal of the American College of Cardiology·A M FeldmanC McTiernan
Feb 13, 2001·Biochemical and Biophysical Research Communications·S Y SunG S Wu
Jun 2, 2001·The New England Journal of Medicine·M PackerUNKNOWN Carvedilol Prospective Randomized Cumulative Survival Study Group
Oct 5, 2001·Journal of the American College of Cardiology·A Al-AhmadM J Sarnak
Dec 12, 2001·Circulation·P RazeghiH Taegtmeyer
Jun 27, 2002·Journal of the American College of Cardiology·Paul R KalraStefan D Anker
Feb 15, 2003·The American Journal of Medicine·Mikhail KosiborodHarlan M Krumholz

❮ Previous
Next ❯

Citations

Jun 22, 2006·Cardiology in Review·Maya E Guglin, Deepak Koul
Feb 3, 2016·Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc·Akihiro HirashikiToyoaki Murohara
Nov 12, 2005·European Journal of Clinical Investigation·W H Hörl, G Ertl
Jun 12, 2016·Diabetes Care·Ele FerranniniEric Mayoux

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.